ExonHit Therapeutics has announced a supply and service provider agreement to combine Affymetrix' GeneChip® microarray platform and ExonHit's alternative RNA splicing technologies and expertise.
The widely used Affymetrix Whole-Transcript Gene 1.0 ST (sense target) microarray platform, normally used to assay gene expression, can also be utilized to interrogate exon-specific splicing. A new ...
Offerings Now Encompass Multiplex and Parallel Analysis of Cells, Proteins, and Genes Affymetrix, best known for its pioneering work in commercializing microarrays for gene expression research since ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix (Nasdaq:AFFX) and Ariosa Diagnostics, Inc. today announced the signing of a multi-year supply agreement covering Affymetrix arrays and instruments to ...
HOUSTON & SANTA CLARA, Calif.--(BUSINESS WIRE)--Family Tree DNA, the first and largest genealogical DNA testing company, today announced the launch of the Family Finder DNA test for connecting family ...
Affymetrix said today it will collaborate with XRGenomics to develop next-generation diagnostic tests for age-related diseases. The alliance builds on an existing partnership between the companies, as ...
Genomatix Software GmbH today announced that it has achieved GeneChip-compatible TM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has ...
Collaboration to expand research and molecular breeding tools for enhancing plant, crop, and livestock production outcomes SANTA CLARA, Calif.--(BUSINESS WIRE)-- Affymetrix, Inc. (NASDAQ:AFFX), ...
Proven Assay Products for Low to Mid-Plex Applications Will Strengthen Company's Position in High-Growth Validation and Routine-Testing Markets SANTA CLARA, Calif.--(BUSINESS WIRE)--Nov. 11, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback